BACKGROUND Long noncoding RNAs (lncRNAs) recently have been implicated in the
pathological processes of
cardiovascular diseases. In this study, LncRNADisease database and PubMed database were used to screen myocardial infraction (MI)-related lncRNAs and to investigate the diagnostic role of lncRNAs in ST-segment elevation myocardial infraction (
STEMI). MATERIAL AND METHODS Forty-six patients with
STEMI and 40 healthy controls were included in the study. Venous blood samples acquired at different time points and the expression levels of lncRNAs in plasma were measured by qRT-PCR. In addition, other blood samples were collected before and after
percutaneous coronary intervention (PCI). Correlation analysis and receiver operating characteristic (ROC) curve were used to assess the diagnosis value of the markers. All included patients were followed up for 12±1 months. RESULTS Nine MI-related lncRNAs were selected from the database. The qRT-PCR results showed that the expression of
hypoxia inducible factor 1A
antisense RNA 2 (aHIF), member 1 opposite strand/antisense transcript 1 (KCNQ1OT1), and mitochondrial
long noncoding RNA uc022bqs.1 (LIPCAR) were significantly increased in patients with
STEMI compared to the control patients. The ROC curve showed that LIPCAR (AUC=0.782, 95% CI: 0.707-0.0.894) had better diagnostic accuracy. Moreover, correlation analysis indicated that LIPCAR were positively correlated with myocardial
enzymes and negatively correlated with left ventricular ejection fraction. The level of LIPCAR in
STEMI patients after PCI was lower (P<0.05). Multivariate regression analysis indicated that higher levels of LIPCAR were independent predictors of major adverse cardiovascular events in patients with
STEMI (HR=5.93; 95% CI, 1.46-9.77; P=0.001). CONCLUSIONS Highly expressed LIPCAR in plasma may serve as a warning sign for the diagnosis of
STEMI.